NASDAQ:ZSAN - Zosano Pharma Stock Price, News & Analysis

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Shares of Zosano Pharma reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

Zosano Pharma Corp (NASDAQ:ZSAN) announced its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.56) by $0.01. View Zosano Pharma's Earnings History.

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Zosano Pharma.

3 equities research analysts have issued 12 month price targets for Zosano Pharma's shares. Their predictions range from $3.66 to $19.00. On average, they expect Zosano Pharma's stock price to reach $10.22 in the next twelve months. This suggests a possible upside of 270.3% from the stock's current price. View Analyst Price Targets for Zosano Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.

News articles about ZSAN stock have been trending negative on Monday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zosano Pharma earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Zosano Pharma.

Zosano Pharma saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 1,360,000 shares, a decrease of 5.9% from the June 30th total of 1,444,600 shares. Based on an average trading volume of 289,000 shares, the short-interest ratio is presently 4.7 days. Currently, 14.5% of the shares of the company are sold short. View Zosano Pharma's Current Options Chain.

Some companies that are related to Zosano Pharma include Galectin Therapeutics (GALT), Cue Biopharma (CUE), Molecular Templates (MTEM), AcelRx Pharmaceuticals (ACRX), Spero Therapeutics (SPRO), Imprimis Pharmaceuticals (IMMY), Constellation Pharmaceuticals (CNST), Adamas Pharmaceuticals (ADMS), Nature's Sunshine Products (NATR), TAIWAN LIPOSOME/S (TLC), Affimed (AFMD), LifeVantage (LFVN), Newron Pharmaceuticals (NWPHF), Poxel (PXXLF) and Applied Therapeutics (APLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Synergy Pharmaceuticals (SGYP), AEterna Zentaris (AEZS), Square (SQ), Anthera Pharmaceuticals (ANTH), Immunomedics (IMMU), Protalix Biotherapeutics (PLX), Evoke Pharma (EVOK), Iovance Biotherapeutics (IOVA), Neovasc (NVCN) and Verastem (VSTM).

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Zosano Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Aisling Capital Management LP (90.29%), Vanguard Group Inc. (5.40%), BlackRock Inc. (2.07%), Wedbush Securities Inc. (0.12%) and Jane Street Group LLC (0.06%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc, John Peter Walker and Kenneth Greathouse. View Institutional Ownership Trends for Zosano Pharma.

ZSAN stock was bought by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, Vanguard Group Inc., BlackRock Inc., Wedbush Securities Inc. and Jane Street Group LLC. Company insiders that have bought Zosano Pharma stock in the last two years include John Peter Walker and Kenneth Greathouse. View Insider Buying and Selling for Zosano Pharma.

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ZSAN stock can currently be purchased for approximately $2.76.

Zosano Pharma has a market capitalization of $48.92 million. The biotechnology company earns $-35,360,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.View Additional Information About Zosano Pharma.

The official website for Zosano Pharma is http://www.zosanopharma.com/.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]